Chiltern International

Berkshire County, United States Founded: 1982 • Age: 44 yrs Acquired By LabCorp
Full service CRO with expertise in oncology related development services

About Chiltern International

Chiltern International is a Healthcare company based in United States founded in 1982, and was acquired by LabCorp in September 2017. Full service CRO with expertise in oncology related development services. Chiltern International has completed 4 acquisitions, including Chiltern, Integrated Development Associates and Pacific Clinical Research. Its Indian entity Chiltern International Private Limited reported revenue of β‚Ή2.70 Cr. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Emmes, Syneos Health and Veristat.

Company details

Chiltern is a full-service CRO focussed on providing clinical research development services in a variety of specialty areas and engagement models for biotech, pharma, biopharma, medical device and diagnostics industries. It provides a suite of services in clinical development, medical scientific affairs, data analysis, pharmacovigilance, strategic regulatory and clinical supplies. It is currently operating in 47 countries with 22,000 investigation sites claims to have conducted 1,800clinical trials. Chilterns offerings are focused on three major areas - Chiltern Oncology (Oncology CRO services across all phases of development), Chiltern Biopharmaceutics (Global CRO services with therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology) , Chiltern Source (Functional Services and Sourcing solutions specializing in customized sourcing solutions for clinical, regulatory, medical and biometrics services.

Key Metrics
  • Indian entity revenue
    ₹2.70 Cr

    FY 2017 · -58% YoY

  • Indian entity net loss
    -₹72.4 Lakh

    FY 2017 · -18% margin

  • Indian entity EBITDA
    -₹45 Lakh

    FY 2017 · -11% margin

  • Investors
    LabCorp

    & 2 more

  • Investments & Acquisitions
    Chiltern

    & 3 more

  • Acquired by
    LabCorp

    & 1 more

    (Sep 2017)

Funding Insights of Chiltern International

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Chiltern International with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2010Private Equity Round––
Valuation history

3 investors in total: 3 institutional.

Investors in Chiltern International

Chiltern International has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Kester Capital and Czura Thornton.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Kester Capital is focused on private equity investments in technology and life sciences sectors.
kestercapital.comLondon, United Kingdom
czurathornton.com
Provider of laboratory tests for physicians
1969labcorp.comBurlington, United States
Premium access

Investor details for Chiltern International

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Chiltern International Private Limited (Chiltern International)

Chiltern International Private Limited is the primary company behind Chiltern International. The board of Chiltern International Private Limited currently have 3 directors; the longest-serving is Sandeep Adsule Dada, appointed in 2012. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sandeep Adsule Dada
DIN 05342475
Director29 Aug 201214 yrs 2 moChiltern International Private Limited
Linda Josephine Green
DIN 06457445
Director21 Dec 201213 yrs 11 moChiltern International Private Limited
Richard Timothy Barfield
DIN 06763918
Director21 Dec 201312 yrs 11 moChiltern International Private Limited

Financials of Chiltern International

Figures of Chiltern International Private Limited, the primary company behind Chiltern International, for FY 2017. Revenue was ₹2.70 Cr (-58% year on year). Net loss was -₹72.4 Lakh (-18% margin). EBITDA was -₹45 Lakh (-11% margin).

  • ₹2.70 CrRevenue · FY 2017 · -58% YoY
  • -₹72.4 LakhNet loss · -18% margin
  • -₹45 LakhEBITDA · -11% margin
  • ₹32.8 LakhPaid-up capital
  • 28Employees (provident fund records)

Balance sheet, profit and loss, cash flow and ratios of Chiltern International Private Limited are on its company page.

Premium access

Detailed financial statements for Chiltern International

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Chiltern International

Chiltern International has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Chiltern, Integrated Development Associates and Pacific Clinical Research.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Full-service CRO, based out of Japan and Asia and also offering regulatory consulting services
i-d-a.comTokyo, Japan2004May 2017β€’β€’β€’β€’
Clinical development services for biopharma and medical devices are provided.
theoremclinical.comKing Of Prussia, United States1985Aug 2015β€’β€’β€’β€’
Clinical trial management services are provided across Asian markets.
pacificcro.comMumbai, India2009Sep 2014β€’β€’β€’β€’
Full-service oncology CRO operations are conducted globally.
ockham.comSacramento, United States1986Jul 2014β€’β€’β€’β€’
Premium access

Complete acquisition details for Chiltern International

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Chiltern International

8 dated milestones of Chiltern International across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded Chiltern International is founded.
  2. Exit Acquired by Czura Thornton.
  3. Funding First funding round.
  4. Acquisition Acquires Chiltern.
  5. Acquisition Acquires Pacific Clinical Research.
  6. Acquisition Acquires Theorem Clinical Research.
  7. Acquisition Acquires Integrated Development Associates.
  8. Exit Acquired by LabCorp.

Competitors of Chiltern International

Chiltern International has 3 listed competitors in our database. They include Emmes, Syneos Health and Veristat.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
emmes.com1977United States195
Outsourced contract research organization services are provided to clients.
syneoshealth.com1984Raleigh, United States29,395
CRO clinical development services are provided by Syneos Health.
veristat.com1994Southborough, United States7
Clinical trials and regulatory submissions are supported as a CRO.
Premium access

Detailed competitors of Chiltern International

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Chiltern International

Websites that share an audience with Chiltern International (chiltern.com).

Similar websites

Websites whose visitors overlap most with Chiltern International. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
richmondpharmacology.com
100%
8.1K#4,561,453View details
illingworthresearch.com
99%
1.2K#11,172,207View details
pharm-olam.com
92%
View details
acr-research.com
acr-research.com
85%
–
premier-research.com
85%
39.9K#825,378View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 23 similar websites and full traffic analytics for Chiltern International

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 23 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Chiltern International (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Chiltern International

Premium access

Complete news archive for Chiltern International

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chiltern International

Chiltern International was founded in 1982 and raised its 1st funding round 28 years after it was founded.

Chiltern International is headquartered in United States. It is registered at Massachusetts, United States.

The primary company behind Chiltern International, Chiltern International Private Limited, reported revenue of β‚Ή2.70 Cr for FY 2017, down 58% year on year.

Chiltern is a full-service CRO focussed on providing clinical research development services in a variety of specialty areas and engagement models for biotech, pharma, biopharma, medical device and diagnostics industries. It provides a suite of services in clinical development, medical scientific affairs, data analysis, pharmacovigilance, strategic regulatory and clinical supplies. It is currently operating in 47 countries with 22,000 investigation sites claims to have conducted 1,800clinical trials. Chilterns offerings are focused on three major areas - Chiltern Oncology (Oncology CRO services across all phases of development), Chiltern Biopharmaceutics (Global CRO services with therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology) , Chiltern Source (Functional Services and Sourcing solutions specializing in customized sourcing solutions for clinical, regulatory, medical and biometrics services.

Chiltern International's top competitors include Emmes, Syneos Health and Veristat.

Chiltern International has made 4 acquisitions, including Chiltern, Integrated Development Associates, and Pacific Clinical Research.

Chiltern International has 3 investors. Key investors include LabCorp, Kester Capital, and Czura Thornton.

Chiltern International operates through Chiltern International Private Limited.

Yes. Chiltern International was acquired by LabCorp in September 2017.

The legal entities of Chiltern International currently have 3 directors, including Sandeep Adsule Dada, Linda Josephine Green, Richard Timothy Barfield.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available